Cabaxan Adverse Reactions

The safety of Cabazitaxel in combination with prednisone or prednisolone was evaluated in 371 patients with metastatic castration resistant prostate cancer who were treated with 25 mg/m² cabazitaxel once every three weeks in randomised open label, controlled phase III study. Patients received a median duration of 6 cycles of cabazitaxel.
The most commonly (≥10%) occurring adverse reactions in all grades were anaemia (97.3%), leukopenia (95.7%), neutropenia (93.5%), thrombocytopenia (47.4%), and diarrhoea (46.6%). The most commonly (≥5%) occurring grade ≥3 adverse reactions in the cabazitaxel group were neutropenia (81.7%), leukopenia (68.2%), anaemia (10.5%), febrile neutropenia (7.5%), diarrhoea (6.2%).
Discontinuation of treatment due to adverse reactions occurred in 68 patients (18.3%) receiving cabazitaxel. The most common adverse reactions leading to cabazitaxel discontinuation was neutropenia.
The following serious adverse reactions are discussed in greater detail in another section (see Precautions): Neutropenia, Hypersensitivity Reactions, Gastrointestinal Disorders, Renal Failure.